Group 1 - Fagron completed a share buy-back program, repurchasing a total of 200,000 shares at an average price of €20.6805, amounting to €4,136,093 [1][2] - The recent buy-back occurred from 10 November 2025 to 14 November 2025, during which 44,000 shares were bought at an average price of €20.7208, totaling €911,717 [1] - The buy-back program was announced on 9 October 2025, and the repurchased shares will be used to meet obligations under Fagron's long-term incentive scheme [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 35 countries [4] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - Operational activities are managed through Fagron BV, which is headquartered in Rotterdam [5] Group 3 - The financial calendar includes key dates such as the full year results for 2025 on 12 February 2026 and the trading update for the first quarter of 2026 on 9 April 2026 [3]

Group 1 - Fagron received a notification from Mawer Investment Management Ltd regarding a change in shareholding, specifically crossing the disclosure threshold of 5% downwards [1][6] - On 29 August 2025, Mawer Investment Management Ltd held a total of 3,632,837 voting rights, which represented 4.96% of the total voting rights based on a denominator of 73,313,904 [6] - The notification indicates that the change in shareholding was due to the disposal of voting securities or voting rights [6] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in over 35 countries [3] - The company is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed through its Dutch subsidiary, Fagron BV, which is headquartered in Rotterdam [4]

Core Points - Fagron received a notification from Alychlo NV regarding a change in shareholding that crossed the disclosure threshold of 3% downwards [1][8] - The notification indicates that Alychlo NV disposed of voting securities or voting rights on 25 July 2024, resulting in a new holding of 2,139,886 voting rights [8] - The total number of voting rights at that time was 73,228,904, meaning Alychlo NV and Marc Coucke together held 2.93% of the total voting rights [8] Company Information - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron has issued 85,000 new shares as a result of the exercise of subscription rights on June 6, 2025 [1] - The total share capital of Fagron currently amounts to €504,303,905.59, with a total of 73,313,904 shares with voting rights [2] - There are 1,465,833 rights to subscribe to not yet issued shares with voting rights [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in 35 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed by its Dutch subsidiary, Fagron BV, headquartered in Rotterdam [4]